Clinical and Pathologic Studies in Neuroendocrine Tumors

Learn more about:
Related Clinical Trial
Bronchoscopic Laser Ablation of Peripheral Lung Tumors Physical Activity Intervention Before and After Surgery in Older Adults With Lung Cancer and Their Family Caregivers Personalized PRRT of Neuroendocrine Tumors Clinical and Pathologic Studies in Neuroendocrine Tumors Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs) Active Surveillance in Early Lung Cancer Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma 68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs) Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors Effect of Oral 5-HTP Intake on Urinary 5-HIAA Excretion Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease Cabozantinib and Nivolumab for Carcinoid Tumors Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors A Combination Study to Determine the Safety and Efficacy of Panzem NCD With Avastin in Metastatic Carcinoid Tumors A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors Endoscopic Treatment of Bronchial Carcinoid Tumors Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors A Study of Axitinib in Advanced Carcinoid Tumors A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors

Brief Title

Clinical and Pathologic Studies in Neuroendocrine Tumors

Official Title

Clinical and Pathologic Studies in Neuroendocrine Tumors

Brief Summary

      This research involves the study of neuroendocrine tumors in order to better understand how
      the disease grows and spreads. This study requires will use tissue collected from from
      biopsies performed during your regular medical care (i.e. tissue leftover after your
      diagnosis has been made) and/or blood and urine samples. This study may lead to the
      development of special materials that could be used, in the future, to treat neuroendocrine
      tumors or to follow the response of neuroendocrine tumors to treatment
    



Study Type

Observational




Condition

Carcinoid Tumor

Intervention

blood sample draw


Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Procedure

Estimated Enrollment

200

Start Date

July 2007

Completion Date

June 2008

Primary Completion Date

June 2008

Eligibility Criteria

        Inclusion Criteria:- Patients are eligible if they have a histologically proven
        neuroendocrine tumor and are 18 years of age or older

        - Ability to understand and the willingness to sign a written informed consent document.
        Exclusion Criteria:None
      

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

George Albert Fisher M.D. Ph.D., , 

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT00657332

Organization ID

SU-12102007-931

Secondary IDs

98132


Study Sponsor

Stanford University


Study Sponsor

George Albert Fisher M.D. Ph.D., Principal Investigator, Stanford University


Verification Date

February 2010